Laurion Capital Management LP Immuno Gen, Inc. Transaction History

Laurion Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $809,027 - $1.94 Million	64,930 New	64,930 $1.93 Million
Q2 2018 Aug 13, 2018	SELL	$9.52 - $12.15 $130,424 - $166,455	-13,700 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $91,790 - $177,415	13,700 New	13,700 $144,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.